Based on the key indicators related to Eyepoint Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Eyepoint Pharmaceuticals may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Eyepoint Pharmaceuticals' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Inventory is likely to gain to about 4.1 M in 2024, despite the fact that Retained Earnings are likely to grow to (705 M). Key indicators impacting Eyepoint Pharmaceuticals' financial strength include:
Investors should never underestimate Eyepoint Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Eyepoint Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Eyepoint Pharmaceuticals.
Net Income
(67.26 Million)
Eyepoint
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Liabilities
Stock Based Compensation
Total Cashflows From Investing Activities
Other Cashflows From Investing Activities
Change To Inventory
Sale Purchase Of Stock
Investments
Change Receivables
Exchange Rate Changes
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Netincome
Change To Operating Activities
Net Borrowings
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Intangible Assets
Common Stock
Common Stock Shares Outstanding
Accounts Payable
Other Assets
Accumulated Other Comprehensive Income
Property Plant Equipment
Current Deferred Revenue
Long Term Debt
Short Term Debt
Other Liab
Short Term Investments
Net Tangible Assets
Retained Earnings Total Equity
Capital Surpluse
Deferred Long Term Liab
Non Current Liabilities Other
Net Invested Capital
Net Working Capital
Long Term Debt Total
Capital Lease Obligations
Capital Stock
Depreciation And Amortization
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling General Administrative
Cost Of Revenue
Selling And Marketing Expenses
Net Income Applicable To Common Shares
Net Income From Continuing Ops
Non Recurring
Non Operating Income Net Other
Net Interest Income
Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Eyepoint Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Eyepoint Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Eyepoint Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Eyepoint Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eyepoint Pharmaceuticals. Check Eyepoint Pharmaceuticals' Beneish M Score to see the likelihood of Eyepoint Pharmaceuticals' management manipulating its earnings.
Eyepoint Pharmaceuticals Stock Summary
Eyepoint Pharmaceuticals competes with Capricor Therapeutics, Soleno Therapeutics, Bio Path, Moleculin Biotech, and Crinetics Pharmaceuticals. EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Eyepoint Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Eyepoint Pharmaceuticals Key Income Statement Accounts
The reason investors look at the income statement is to determine what Eyepoint Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Eyepoint Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Eyepoint Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eyepoint Pharmaceuticals competition to find correlations between indicators driving Eyepoint Pharmaceuticals's intrinsic value. More Info.
Eyepoint Pharmaceuticals is rated # 4 in return on equity category among its peers. It is rated # 5 in return on asset category among its peers . At this time, Eyepoint Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Eyepoint Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Eyepoint Pharmaceuticals Systematic Risk
Eyepoint Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Eyepoint Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Eyepoint Pharmaceuticals correlated with the market. If Beta is less than 0 Eyepoint Pharmaceuticals generally moves in the opposite direction as compared to the market. If Eyepoint Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Eyepoint Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Eyepoint Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Eyepoint Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Eyepoint Pharmaceuticals Thematic Clasifications
Eyepoint Pharmaceuticals is part of Measuring and Control Equipment investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Measuring and Control Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Measuring and Control Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Eyepoint Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eyepoint Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Eyepoint Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.31
At this time, Eyepoint Pharmaceuticals' Price Earnings To Growth Ratio is comparatively stable compared to the past year.
Eyepoint Pharmaceuticals November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Eyepoint Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Eyepoint Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Eyepoint Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Eyepoint Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Eyepoint Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.